Titre du document / Document title

Pityriasis versicolor : Clinical experience with Lamisil® cream and Lamisil® DermGel

Auteur(s) / Author(s)

FAERGEMANN J. ⁽¹⁾ ; HERSLE K. ⁽²⁾ ; NORDIN P. ⁽²⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Department of Dermatology, Sahlgrenska University Hospital, Gothenburg, SUEDE
⁽²⁾ Department of Dermatology, Frolunda Hospital, Vastra Frolunda, SUEDE

Résumé / Abstract

Pityriasis versicolor is a chronic superficial fungal disease usually located on the upper trunk, neck or upper arms. Terbinafine is an orally and topically active allylamine antifungal derivative with a broad antifungal spectrum. Several studies have documented the high activity of terbinafine (Lamisil®) cream in the treatment of pityriasis versicolor, with cure rates of 79-100% after 2-4 weeks of treatment. Lamisil emulsion gel (Lamisil® DermGel) is a new topical formulation that remains in the skin in high concentrations for several months after just 1 week of application. Recently, in a prospective, double-blind, placebo-controlled, randomised, parallel-group, comparative, multicentre study, we have treated patients with pityriasis versicolor with either terbinafine 1% emulsion gel (Lamisil DermGel) or placebo gel. Sixty-one patients were included, 31 in the Lamisil DermGel group and 30 in the placebo gel group. The gel was applied once daily for 7 days and the patients were followed up for 8 weeks. Twenty-eight patients in the active and 29 patients in the placebo group were evaluable for efficacy. Using the intent-to-treat efficacy analysis, 21/28 (75%) were cured in the Lamisil-DermGel-treated group compared to 4/29 (14%) in the placebo group. No side-effects were seen. In conclusion, Lamisil DermGel was well tolerated and superior to placebo in the treatment of pityriasis versicolor when applied once daily for 7 days.

Revue / Journal Title

Dermatology   ISSN 1018-8665 

Source / Source

Congrès
Topical Lamosil® : New Indications and Dosage Forms. Satellite Symposia, Vancouver , CANADA (28/05/1996)
1997, vol. 194, SUP1, pp. 3-24 (6 ref.), [Notes: Satellite symposium of Clinical Dermatology 2000], pp. 19-21

Langue / Language

Anglais

Editeur / Publisher

Karger, Basel, SUISSE  (1992) (Revue)

Mots-clés anglais / English Keywords

Pityriasis versicolor ; Treatment ; Chemotherapy ; Terbinafine ; Antifungal agent ; Freeze ; Dosage form ; Randomization ; Double blind study ; Tolerance ; Human ; Allylic compound ; Amine ; Mycosis ; Infection ; Skin disease ; Pigmentation disorder ;

Mots-clés français / French Keywords

Pityriasis versicolor ; Traitement ; Chimiothérapie ; Terbinafine ; Antifongique ; Gel ; Forme pharmaceutique ; Randomisation ; Etude double insu ; Tolérance ; Homme ; Composé allylique ; Amine ; Mycose ; Infection ; Peau pathologie ; Trouble pigmentation ;

Mots-clés espagnols / Spanish Keywords

Pitiriasis versicolor ; Tratamiento ; Quimioterapia ; Terbinafina ; Antifúngico ; Helada ; Forma farmacéutica ; Aleatorización ; Estudio doble ciego ; Tolerancia ; Hombre ; Compuesto alílico ; Amina ; Micosis ; Infección ; Piel patología ; Trastorno pigmentación ;

Localisation / Location

INIST-CNRS, Cote INIST : 4530, 35400006526447.0050